UnitedHealth Q4 EPS Tops Estimates and Alpha Cubed Boosts Stake 250%

UNHUNH

UnitedHealth reported Q4 EPS of $2.11, beating consensus by $0.02 on revenue of $113.22 billion, up 12.3%. CMS proposed a minimal 2027 Medicare Advantage rate hike and Alpha Cubed raised its UnitedHealth stake by 250.5% to 124,682 shares worth $43.1 million.

1. Significant Stake Increase by Alpha Cubed Investments

Alpha Cubed Investments LLC expanded its position in UnitedHealth Group by 250.5% during the third quarter, boosting its holdings to 124,682 shares after acquiring an additional 89,105 shares. This stake now represents approximately 1.5% of the firm’s portfolio, ranking UNH as its 18th largest position. At the end of the reporting period, the total value of Alpha Cubed’s UNH shares stood at $43.05 million, underscoring growing institutional conviction in the health care conglomerate’s long-term prospects.

2. Broad Institutional Interest and Ownership Concentration

In the second and third quarters, several boutique and regional firms initiated new positions in UnitedHealth Group. LFA Lugano Financial Advisors, Sagard Holdings Management, Islay Capital Management, Cloud Capital Management, and Grey Fox Wealth Advisors each added stakes valued between $25,000 and $33,000. Collectively, hedge funds and other institutional investors now control 87.86% of UNH’s outstanding shares, highlighting the stock’s prominence among professional asset allocators and reinforcing its defensive profile within the health care sector.

3. Analyst Ratings Reflect Consensus Optimism

Equity research desks have maintained an upbeat stance on UnitedHealth Group. Following a Zacks Research upgrade to Hold, JPMorgan Chase raised its price target and reiterated an Overweight rating, while Piper Sandler and KeyCorp reaffirmed their Overweight designations. Although Morgan Stanley trimmed its target marginally, all major brokerages continue to endorse UNH, with 17 Buy ratings, 9 Hold ratings and only 2 Sell ratings. The average consensus rating remains Moderate Buy, supported by robust earnings growth and defensive revenue streams across UnitedHealthcare and Optum segments.

4. Strong Q4 Performance and Dividend Commitment

In its latest quarterly report, UnitedHealth Group delivered adjusted EPS of $2.11, surpassing consensus by $0.02, on revenue of $113.22 billion, reflecting 12.3% year-over-year growth. Return on equity reached 14.79% with a net margin of 2.69%. Management set full-year guidance for EPS at 17.75, with analysts projecting approximately 29.54 for the current fiscal year. The company also declared a quarterly dividend of $2.21 per share, representing an annualized payout of $8.84 and a yield near 3.0%, underscoring its commitment to shareholder returns while balancing reinvestment in AI-driven efficiencies and margin expansion initiatives.

Sources

SSFSZ
+2 more